Achilles Therapeutics PLC ADR (ACHL)vsInsmed Inc (INSM)
ACHL
Achilles Therapeutics PLC ADR
$1.48
0.00%
HEALTHCARE · Cap: $63.22M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
ACHL leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ACHL
Avoid32
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ACHL
The strongest argument for ACHL centers on Price/Book.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ACHL
The primary concerns for ACHL are Revenue Growth, EPS Growth, Market Cap.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ACHL profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
ACHL carries more volatility with a beta of 1.25 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Achilles Therapeutics PLC ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?